Breaking News Instant updates and real-time market news.

CLIR

ClearSign Combustion

$3.60

-0.1 (-2.70%)

, CTIC

CTI BioPharma

$3.39

0.04 (1.19%)

17:49
07/13/17
07/13
17:49
07/13/17
17:49

On The Fly: After Hours Movers

HIGHER: ClearSign Combusion (CLIR), up 16.7% after it received a purchase order from a supermajor oil company to qualify its Duplex combustion technology... CTI BioPharma (CTIC), up 11.8% after its Marketing Authorization Application for pacritinib was validated by the European Medicines Agency... Celadon Group (CGI), up 10.6% after it named Paul Svindland to succeed Paul Will as chief executive officer... Sangamo (SGMO), up 4.7% after its MPS candidates were granted Fast Track designation by the FDA... Mylan (MYL), up 2.2% after it said that the FDA's Oncologic Drugs Advisorty Committee recommended the approval of Mylan and Biocon's proposed biosimilar trastuzumab. LOWER: CyberArk (CYBR), down 18.2% after it cut its revneue guidance for Q2 due to its performance in EMEA... A10 Netorks (ATEN), down 17% after it lowered its guidance for Q2, saying a number of opportunities in its pipeline did not close primarily in North America and to a lesser degree in Japan.

CLIR

ClearSign Combustion

$3.60

-0.1 (-2.70%)

CTIC

CTI BioPharma

$3.39

0.04 (1.19%)

CGI

Celadon Group

$2.35

-0.05 (-2.08%)

SGMO

Sangamo

$9.50

0.25 (2.70%)

MYL

Mylan

$39.05

0.47 (1.22%)

CYBR

CyberArk

$51.00

0.56 (1.11%)

ATEN

A10 Networks

$8.24

0.03 (0.37%)

  • 13

    Jul

  • 13

    Jul

  • 08

    Aug

  • 08

    Aug

  • 03

    Sep

  • 09

    Oct

CLIR ClearSign Combustion
$3.60

-0.1 (-2.70%)

CTIC CTI BioPharma
$3.39

0.04 (1.19%)

CGI Celadon Group
$2.35

-0.05 (-2.08%)

04/06/17
AGIS
04/06/17
NO CHANGE
Target $15
AGIS
Buy
Aegis says Celadon short report concerns 'largely repackaged and republished'
Aegis analyst Jeffrey Kauffman said some of the concerns raised in the short report published on Celadon Group yesterday are "interesting and thought provoking," but he also views them as "largely repackaged and republished" from similar reports from 2016. Some of reports' assertions are factually accurate, but they are used in a distorted ways to arrive at a factually inaccurate conclusion, said the analyst , who views the pullback yesterday as a buying opportunity. Kauffman keeps a Buy rating and $15 price target on Celadon shares, which slid nearly 15% following Prescience Point Research's report.
01/12/17
01/12/17
UPGRADE
Target $11

Buy
Celadon Group upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Rhem Wood upgraded Celadon Group to Buy from Neutral with an $11 price target saying the joint-venture spinoff allows the company to refocus on its core trucking business. Despite a lot of noise in the investor community recently, Wood believes the negatives have been overstated, and earnings are currently at the trough with substantial upside from here.
02/10/17
STFL
02/10/17
UPGRADE
Target $10
STFL
Hold
Celadon Group upgraded to Hold from Sell at Stifel
Stifel analyst John Larkin upgraded Celadon Group to Hold with a $10 price target. The analyst said Truckload sector expectations have come down materially across the Street and believes we are now entering a more constructive period of investing as economic improvement could benefit freight volumes.
03/02/17
AGIS
03/02/17
INITIATION
Target $15
AGIS
Buy
Celadon Group initiated with a Buy at Aegis
Aegis analyst Jeffrey Kauffman initiated Celadon Group with a Buy and a $15 price target saying it trades at a 36% discount to its book value and is one of a few trucking equities that remain undervalued because of a lack of following and concerns about factors that have been largely alleviated.
SGMO Sangamo
$9.50

0.25 (2.70%)

09/06/16
WELS
09/06/16
NO CHANGE
WELS
Outperform
Wells calls Sangamo an 'attractive new investment opportunity'
After the FDA granted orphan drug designation to its Factor IX gene-editing product candidate, SB-FIX, as a treatment for hemophilia B, Wells Fargo analyst Jim Birchenough calls Sangamo BioSciences an "attractive new investment opportunity." Along with validating a commercial opportunity in hemophilia, SB-FIX could provide "even more valuable validation of targeting and coopting the albumin gene locus for gene insertion that may apply to a wide variety of genetic diseases," Birchenough tells investors in a research note. He keeps an Outperform rating on the shares.
08/04/16
JANY
08/04/16
DOWNGRADE
JANY
Neutral
Sangamo downgraded to Neutral from Buy at Janney Capital
11/01/16
WEDB
11/01/16
DOWNGRADE
WEDB
Neutral
Sangamo downgraded to Neutral from Outperform at Wedbush
10/19/16
PIPR
10/19/16
DOWNGRADE
PIPR
Neutral
Sangamo downgraded to Neutral from Overweight at Piper Jaffray
MYL Mylan
$39.05

0.47 (1.22%)

06/16/17
CANT
06/16/17
INITIATION
Target $41
CANT
Neutral
Mylan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Mylan with a Neutral rating and $41 price target.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Market Perform
Wells wouldn't be surprised to see greater scrutiny on Mylan coal tax credits
After a new report from Reuters questioned the way in which Mylan uses its ownership of coal processing plants to keep its taxes low, Wells Fargo analyst David Maris said this topic has interested him for some time but his questions to management on the issue were not answered. Maris, who said he would not be surprised to see greater public scrutiny on this issue after the report, keeps a Market Perform rating on Mylan shares.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.
05/31/17
WELS
05/31/17
NO CHANGE
WELS
Market Perform
Pension fund campaign a short-term negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris believes the campaign by four major pension funds to oppose the re-election of six directors is short-term negative for Mylan but has the potential to be a longer term positive. The campaign may pose a distraction to management, but if successful, it could address some governance concerns regarding compensation and performance at the company, Maris tells investors in a research note. The analyst has a Market Perform rating on Mylan shares.
CYBR CyberArk
$51.00

0.56 (1.11%)

05/15/17
JMPS
05/15/17
NO CHANGE
JMPS
CyberArk, Proofpoint should gain from ransomware attack, says JMP Securities
JMP Securities analyst Erik Suppiger says that CyberArk (CYBR) and ProofPoint (PFPT) are particularly well-positioned in the wake of the recent ransomware attack. The analyst says that those companies' solutions "most acutely address ransomware attacks." He recommends buying both stocks but is more upbeat on CyberArk, as he thinks that the stock's 12% decline in the wake of its earnings creates a buying opportunity.
05/15/17
OPCO
05/15/17
NO CHANGE
OPCO
FireEye poised for increased demand after ransomware attack, says Oppenheimer
Oppenheimer analyst Shaul Eyal notes that according to media reports, a global ransomware attack was launched and infected up to 200,000 computers in at least 150 countries on Friday. The analyst believes the "biggest ransomware outbreak ever" could serve as a wake-up call for many organizations and countries delaying a review of their cybersecurity hygiene. In that regard, Eyal believes all cybersecurity vendors under his coverage, namely Check Point (CHKP), CyberArk (CYBR), Fortinet (FTNT), Imperva (IMPV), Mimecast (MIME), Palo Alto Networks (PANW), Splunk (SPLK), Symantec (SYMC), Verint (VRNT), but most notably FireEye (FEYE), are poised for increased demand, particularly in the EMEA region where the attacks were largely focused.
05/12/17
IMPC
05/12/17
DOWNGRADE
Target $55
IMPC
In-Line
CyberArk downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Michael Kim downgraded CyberArk to In-Line from Outperform and lowered his price target on the stock to $55 from $63, stating that he thinks the stock could be range-bound until it sees a stronger acceleration in license revenue and increased visibility from the company's acquisition of Conjur.
06/20/17
EVER
06/20/17
NO CHANGE
EVER
CyberArk, Imperva added to Small'Medium Ideas List at Evercore ISI
Evercore ISI analyst Ken Talanian added CyberArk (CYBR) and Imperva (IMPV) to the firm's Small/Medium Core Ideas List and dropped FireEye (FEYE) and Proofpoint (PFPT) from the list. The analyst says that CyberArk and Imperva are better positioned to benefit from the EU's General Data Protection Regulation, or GDPR, which seeks to strengthen the bloc's data security capabilities by forcing companies to meet certain standards by May 2018. The analyst says that CyberArk is well-positioned to be boosted by GDPR because of its focus on insider threats, while Imperva's focus on data security makes it "especially likely to benefit" from GDPR, according to the analyst.
ATEN A10 Networks
$8.24

0.03 (0.37%)

10/31/16
DADA
10/31/16
UPGRADE
DADA
Buy
A10 Networks upgraded on valuation at DA Davidson
As noted earlier, DA Davidson upgraded A10 Networks to Buy from Neutral. Analyst Mark Kelleher upgraded the stock based on valuation. He says that the company "remains well-positioned in its core ADC and DDoS markets" despite its September quarter revenue miss. Target $10.50.
10/31/16
DADA
10/31/16
UPGRADE
DADA
Buy
A10 Networks upgraded to Buy from Neutral at DA Davidson
10/28/16
10/28/16
DOWNGRADE

Perform
A10 Networks downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Ittai Kidron downgraded A10 Networks to Perform from Outperform following mixed Q3 results. The analyst attributes the challenges largely to bad timing and does not believe they raise any larger execution-related red flags. Nonetheless, Kidron is unsure that A10 Networks can deliver the magnitude of quarterly upside needed to move the stock materially higher, especially as it works to maintain a low level of profitability.
10/28/16
OPCO
10/28/16
DOWNGRADE
OPCO
Perform
A10 Networks downgraded to Perform from Outperform at Oppenheimer

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.